Last reviewed 2026-04-20 · How we verify

Sovaldi

At a glance

Approved indications

• Chronic hepatitis C
• Compensated cirrhosis
• Decompensated cirrhosis of liver

Common side effects

• Fatigue
• Headache
• Nausea
• Insomnia
• Anemia

Serious adverse events

• Pancytopenia
• Severe depression
• Suicidal ideation
• Suicide
• Bilirubin elevation (>2.5×ULN)
• Creatine kinase elevation (≥10×ULN)
• Lipase elevation (>3×ULN)
• Neutropenia

Key clinical trials

• People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
• A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients (PHASE2)
• Implementing Low-Barrier HCV Treatment in a Jail Setting (PHASE4)
• Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients (NA)
• Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (PHASE4)
• Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (PHASE2)
• C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV (PHASE3)
• SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Sovaldi CI brief — competitive landscape report
• Sovaldi updates RSS · CI watch RSS
• Genuine Research Center, Egypt portfolio CI